Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Lower advertising and promotional expenses in the same period of the previous year related to the launch of “Tansa fatty acid,” more efficient promotional activities, the solid performance of “Bifina” in Asia, domestic inbound demand, and sales driven by flavor capsules.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥6,665 million (YoY +2.3%) |
| Operating profit | ¥627 million (YoY +128.5%) |
| Ordinary income | ¥663 million (YoY +122.4%) |
| Profit attributable to owners of the parent | ¥466 million (YoY +115.0%) |
| Net income per share | ¥113.65 |
| Equity ratio | End of the current fiscal period 68.7 / End of previous period 69.7 |
| Total assets | ¥19,705 million |
| Net assets | ¥13,542 million |
| Cash flows from operating activities | ¥673 million |
| Cash flows from investing activities | ¥-1,167 million |
| Cash flows from financing activities | ¥395 million |
| Cash and cash equivalents at end of period | ¥1,730 million |
| Full-year earnings forecast | Net Sales ¥12,400 million (YoY -2.3%) / Operating profit ¥650 million (YoY -6.1%) / Ordinary income ¥700 million (YoY -9.5%) / Net income ¥530 million (YoY -15.7%) |
| Annual Dividend Forecast | ¥65 → ¥65（0.0%） |
| Segment revenue | ¥2,401 million (YoY +6.7%), ¥4,255 million (YoY -0.2%), ¥8 million (YoY +132.8%) |
| Segment profit | ¥157 million, ¥469 million (YoY +4.9%), ¥1 million |
| Depreciation and amortization | ¥341 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses on Investment Securities ¥18 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 4,150,000 |
| Treasury Shares at Period-End | 42,625 |
| Factors Behind Changes in Business Performance | Lower advertising and promotional expenses in the same period of the previous year related to the launch of “Tansa fatty acid,” more efficient promotional activities, the solid performance of “Bifina” in Asia, domestic inbound demand, and sales driven by flavor capsules. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Consumer Business, profit increased due to lower advertising and promotional expenses related to the launch of “Tansa fatty acid” in the same period of the previous year and more efficient promotional activities. Sales were also supported by the solid performance of “Bifina” in Asia and domestic inbound demand.